Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Completed 4

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3Plasma cell 2Other solid neoplasm 1

Conditions

Plasmacytoma 2Paraproteinemias 2Multiple Myeloma 2Leukemia, Plasma Cell 2Preleukemia 1Leukemia, Myeloid, Acute 1Advanced Solid Tumors 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × filanesib × Clear all
NCT00637052 2021-02-08

A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia

Pfizer

Phase 1/2 Completed
36 enrolled
Other hematologic neoplasm

Preleukemia, Leukemia, Myeloid, Acute

NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT00462358 2020-09-28

A Study of ARRY-520 in Patients With Advanced Cancer

Array BioPharma

Phase 1 Completed
41 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡